Back To TOP

We Focus on Access so
You Can Focus on Health

Connecting your patients to ZELBORAF® (vemurafenib).
Welcome to ZELBORAF Access Solutions.

I am a
Learn More About
  • LEARN about treatment with Zelboraf
  • FIND the right patient assistance program with our Compass for Patient Access tool
  • LEARN HOW the Genentech BioOncology Co-pay Card can help with the out-of-pocket costs for ZELBORAF
  • Download: new forms for enrollment in GATCF
  • Form Statement of Medical Necessity
  • Form Patient Authorization and Notice of Release of Information

ZELBORAF Indication and Important Safety Information


ZELBORAF® (vemurafenib) tablets are indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

ZELBORAF is not indicated for use in patients with wild-type BRAF melanoma.

Important Safety Information

The following can occur in patients treated with ZELBORAF:

  • New primary malignancies including cutaneous squamous cell carcinoma, non-cutaneous squamous cell carcinoma, new primary melanoma, and other malignancies
  • Tumor promotion in BRAF wild-type melanomas
  • Serious hypersensitivity reactions including anaphylaxis
  • Severe dermatologic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
  • QT prolongation
  • Hepatotoxicity including liver laboratory abnormalities, and, when concurrently administered with ipilimumab, increases in transaminases and bilirubin
  • Photosensitivity
  • Ophthalmologic reactions

ZELBORAF can cause fetal harm when administered to a pregnant woman based on its mechanism of action.

The most common adverse reactions of any grade (≥30%) reported were arthralgia, rash, alopecia, fatigue, photosensitivity reaction, nausea, pruritus, and skin papilloma.

You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555.

Please see accompanying full Prescribing Information for additional important safety information.

ZELBORAF® and the Access Solutions logo are registered trademarks of Genentech, Inc.